In today’s recent session, 0.52 million shares of the Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) have been traded, and its beta is 1.93. Most recently the company’s share price was $4.40, and it changed around -$0.03 or -0.63% from the last close, which brings the market valuation of the company to $907.47M. BCRX at last check was trading at a discount to its 52-week high of $9.06, offering almost -105.91% off that amount. The share price’s 52-week low was $4.27, which indicates that the recent value has risen by an impressive 2.95% since then. We note from Biocryst Pharmaceuticals Inc.’s average daily trading volume that its 3-month average coming to 3.12 million.
Biocryst Pharmaceuticals Inc. stock received a consensus recommendation rating of Buy, based on a mean score of 1.33. If we narrow it down even further, the data shows that 1 out of 10 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 2 recommended BCRX as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Biocryst Pharmaceuticals Inc. is expected to report earnings per share of $BioLineRx Ltd. for the current quarter.
Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) trade information
Instantly BCRX has been showing red trend so far today with a performance of -0.63% on intraday trading today. The performance over the last five days has remained in the red territory. The company’s shares are currently down -26.51% year-to-date, but still down -5.74% over the last five days. On the other hand, Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) is -19.82% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $19, which translates to bulls needing to increase their stock price by 76.84% from its current value. Analyst projections state that BCRX is forecast to be at a low of $14 and a high of $25.
Biocryst Pharmaceuticals Inc. (BCRX) estimates and forecasts
Biocryst Pharmaceuticals Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -23.04 percent over the past six months and at a 32.00% annual growth rate that is well above the industry average of 10.20%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -3.73%. Biocryst Pharmaceuticals Inc. earnings are expected to increase by 42.88% in 2024, but the outlook is positive 44.80% per year for the next five years.
